JP2018511326A5 - - Google Patents

Download PDF

Info

Publication number
JP2018511326A5
JP2018511326A5 JP2017551164A JP2017551164A JP2018511326A5 JP 2018511326 A5 JP2018511326 A5 JP 2018511326A5 JP 2017551164 A JP2017551164 A JP 2017551164A JP 2017551164 A JP2017551164 A JP 2017551164A JP 2018511326 A5 JP2018511326 A5 JP 2018511326A5
Authority
JP
Japan
Prior art keywords
protoxin
pain
variant
seq
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017551164A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018511326A (ja
JP6985151B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/025247 external-priority patent/WO2016161100A1/en
Publication of JP2018511326A publication Critical patent/JP2018511326A/ja
Publication of JP2018511326A5 publication Critical patent/JP2018511326A5/ja
Priority to JP2021153626A priority Critical patent/JP2022008474A/ja
Application granted granted Critical
Publication of JP6985151B2 publication Critical patent/JP6985151B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017551164A 2015-04-02 2016-03-31 プロトキシン−ii変異体及びその使用方法 Expired - Fee Related JP6985151B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021153626A JP2022008474A (ja) 2015-04-02 2021-09-21 プロトキシン-ii変異体及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562142069P 2015-04-02 2015-04-02
US62/142,069 2015-04-02
PCT/US2016/025247 WO2016161100A1 (en) 2015-04-02 2016-03-31 Protoxin-ii variants and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021153626A Division JP2022008474A (ja) 2015-04-02 2021-09-21 プロトキシン-ii変異体及びその使用方法

Publications (3)

Publication Number Publication Date
JP2018511326A JP2018511326A (ja) 2018-04-26
JP2018511326A5 true JP2018511326A5 (https=) 2019-05-09
JP6985151B2 JP6985151B2 (ja) 2021-12-22

Family

ID=57006450

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017551164A Expired - Fee Related JP6985151B2 (ja) 2015-04-02 2016-03-31 プロトキシン−ii変異体及びその使用方法
JP2021153626A Withdrawn JP2022008474A (ja) 2015-04-02 2021-09-21 プロトキシン-ii変異体及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021153626A Withdrawn JP2022008474A (ja) 2015-04-02 2021-09-21 プロトキシン-ii変異体及びその使用方法

Country Status (16)

Country Link
US (3) US10463714B2 (https=)
EP (2) EP3277304B1 (https=)
JP (2) JP6985151B2 (https=)
KR (1) KR20170134542A (https=)
CN (1) CN107921089A (https=)
AR (1) AR104173A1 (https=)
AU (2) AU2016242905B2 (https=)
BR (1) BR112017020896A2 (https=)
CA (1) CA2981336A1 (https=)
ES (1) ES2888799T3 (https=)
IL (2) IL254599B (https=)
MA (1) MA41864A (https=)
MX (1) MX2017012654A (https=)
TW (1) TW201708249A (https=)
UY (1) UY36602A (https=)
WO (1) WO2016161100A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10414808B2 (en) 2012-05-18 2019-09-17 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
MX2016004282A (es) 2013-10-03 2016-10-12 Janssen Biotech Inc Variantes de protoxina-ii y metodos de uso.
MA41642A (fr) 2015-03-03 2018-01-09 Janssen Biotech Inc Variants de protoxine ii et méthodes d'utilisation
EP3277304B1 (en) 2015-04-02 2021-08-04 Janssen Biotech, Inc. Protoxin-ii variants and methods of use
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
CN109369784B (zh) * 2018-11-14 2019-08-30 青海芬陀利华生物科技有限公司 PaTx-1毒素及其应用
US20230241259A1 (en) * 2020-06-10 2023-08-03 Memorial Sloan Kettering Cancer Center IMAGING COMPOUNDS SELECTIVE FOR NaV1.7

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309989A (en) 1976-02-09 1982-01-12 The Curators Of The University Of Missouri Topical application of medication by ultrasound with coupling agent
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
WO1998046722A1 (en) 1997-04-16 1998-10-22 Unigene Laboratories Inc. Direct expression of peptides into culture media
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion A system for administering drugs through the skin
PT1015576E (pt) 1997-09-16 2005-09-30 Egea Biosciences Llc Metodo para a sintese quimica completa e montagem de genes e de genomas
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US20030148273A1 (en) * 2000-08-26 2003-08-07 Shoulian Dong Target enrichment and amplification
EP1348466A3 (en) 2002-02-01 2003-10-29 Inspire Pharmaceuticals, Inc. Method for treating pain with adenosine-tetraphosphates
US7659082B2 (en) 2002-02-19 2010-02-09 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
CA2626584A1 (en) 2005-11-04 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of nav1.8 gene
WO2007109324A2 (en) 2006-03-21 2007-09-27 Xenon Pharmaceuticals, Inc. Potent and selective nav 1.7 sodium channel blockers
US8283318B2 (en) 2006-09-08 2012-10-09 Mayo Foundation For Medical Education And Research Aquaretic and natriuretic polypeptides lacking vasodilatory activity
US7998980B2 (en) 2006-09-15 2011-08-16 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
PE20081140A1 (es) 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
CN102202677A (zh) 2008-09-03 2011-09-28 阿尔伯维塔公司 治疗疼痛的活性剂和方法
WO2010104115A1 (ja) 2009-03-10 2010-09-16 独立行政法人産業技術総合研究所 膜タンパク質を特異的に認識するポリペプチドの調製方法
AU2010296994B2 (en) 2009-09-15 2013-09-19 Alomone Preclinical Ltd. Novel peptides isolated from spider venom, and uses thereof
AU2011224534B2 (en) 2010-03-08 2014-10-09 Dana-Farber Cancer Institute, Inc. Full COLD-PCR enrichment with reference blocking sequence
US9279003B2 (en) 2010-07-07 2016-03-08 Purdue Pharma L.P. Analogs of sodium channel peptide toxin
CN101979411A (zh) 2010-10-21 2011-02-23 湖南师范大学 虎纹捕鸟蛛蛋白酶抑制剂
JP2014507136A (ja) 2011-01-18 2014-03-27 アムジエン・インコーポレーテツド NaV1.7ノックアウトマウスとそれらの使用
KR20210056458A (ko) * 2011-05-04 2021-05-18 바이오셉트 인코포레이티드 핵산 서열 변이체를 검출하는 방법
CA2873860A1 (en) 2012-05-18 2013-11-21 Janssen Biotech, Inc. Huwentoxin-iv variants and methods of use
US10414808B2 (en) 2012-05-18 2019-09-17 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
US9102751B2 (en) 2012-05-18 2015-08-11 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
US9718865B2 (en) 2012-07-27 2017-08-01 Purdue Pharma L.P. Sodium channel blocking peptides and the use thereof
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
CN104065367B (zh) 2013-03-20 2017-11-07 江苏多维科技有限公司 一种低功耗磁电阻开关传感器
MX2016004282A (es) * 2013-10-03 2016-10-12 Janssen Biotech Inc Variantes de protoxina-ii y metodos de uso.
MA41642A (fr) 2015-03-03 2018-01-09 Janssen Biotech Inc Variants de protoxine ii et méthodes d'utilisation
EP3277304B1 (en) 2015-04-02 2021-08-04 Janssen Biotech, Inc. Protoxin-ii variants and methods of use

Similar Documents

Publication Publication Date Title
JP2018511326A5 (https=)
TWI670281B (zh) Gip-glp-1雙重促效劑化合物及方法
TWI642682B (zh) 升糖素類似物
Zhang et al. Advances in developing ACE2 derivatives against SARS-CoV-2
KR101667948B1 (ko) 글루카곤 유사체
JP5762001B2 (ja) プロテアーゼ安定化インスリンアナログ
WO2009142307A1 (ja) 目的ペプチドの血漿中半減期延長作用を有するペプチド
US10077290B2 (en) Stabilized antiviral fusion helices
JP7183164B2 (ja) Pac1受容体作動薬(maxcap)及びその用途
JP2014040483A5 (https=)
JP2013538564A (ja) 抗ウイルス剤
RU2017119773A (ru) Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение
US20240041977A1 (en) Annexin a1 n-terminal peptide formulations and methods
CN110945010A (zh) 肽组合物和相关方法
JPH08501055A (ja) 神経ペプチドチロシンの生物学的機能を抑制する新規な分子
ECSP055961A (es) Formulaciones parenterales de péptidos para el tratamiento de lupus eritematoso sistémico
WO2013036622A2 (en) Antiviral peptides effective against hepatitis c virus
US9757428B2 (en) Designed peptides for tight junction barrier modulation
KR20210010931A (ko) 집먼지진드기 알레르기의 치료 및 예방
KR102449653B1 (ko) Kv1.3 칼륨 채널 길항제
US11299518B2 (en) Fusion respiratory syncytial virus inhibitors and use thereof
JP2008528500A (ja) Mansの構造に基づくムチン過剰分泌抑制剤及び使用方法
WO2016063969A1 (ja) ヘマグルチニン結合ペプチド
JP2018070571A (ja) 免疫誘導剤
CN113412116A (zh) 用于心脏保护的经修饰的轴突生长诱向因子-1肽和组合物